Lv2
106 积分 2023-11-01 加入
Red Blood Cell Transfusion
2天前
已完结
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
2天前
已完结
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
18天前
已完结
359P Overall survival of palbociclib (PAL) + endocrine therapy (ET) in Japanese patients with hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in the 1st line (1L) or 2nd line (2L) setting: A multicenter observational study
18天前
已关闭
前列腺癌骨转移和骨相关疾病临床诊疗专家共识(2021年版)
19天前
已完结
Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial
19天前
已关闭
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial
19天前
已完结
Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre
2个月前
已完结
2015中国肾癌靶向治疗药物不良反应管理专家共识
2个月前
已完结
抗肿瘤药物相关间质性肺病诊治专家共识
2个月前
已完结
皖公网安备34019202002308
